# Assessment and Tracking of Long-term Alefacept Safety

> **NCT00454701** · — · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 1897 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Alefacept exposure

## Key facts

- **NCT ID:** NCT00454701
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 1897 (ACTUAL)
- **Why stopped:** The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing, distribution and sales of Amevive
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454701, "Assessment and Tracking of Long-term Alefacept Safety". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00454701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*